Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion.
- Author:
Kee Won KIM
1
;
Suk Young PARK
;
Myung Sook KIM
;
Seok Chan KIM
;
Eun Hee LEE
;
So Young SHIN
;
Jong Ho LEE
;
Jong Bum KWEON
;
Kuhn PARK
Author Information
1. Department of Internal Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Pleural effusion;
Intrapleural chemotherapy;
Cisplatin;
Cytarabine
- MeSH:
Chest Tubes;
Cisplatin*;
Cytarabine*;
Drainage;
Drug Therapy*;
Follow-Up Studies;
Humans;
Lung Neoplasms;
Pleural Effusion;
Pleural Effusion, Malignant*;
Prospective Studies;
Recurrence
- From:Cancer Research and Treatment
2004;36(1):68-71
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m2 plus cytarabine 1200 mg/m2 in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE. RESULTS: The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable. CONCLUSION: The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.
